DARE
Daré Bioscience, Inc.
Biotechnology
Market Cap$25M
5Y Perf.-76.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
DARE vs CRVS
Revenue, margins, valuation, and 5-year total return — side by side.
CRVS
Corvus Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.23B
5Y Perf.+322.9%
DARE vs CRVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | DARE | CRVS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $25M | $1.23B |
| Revenue (TTM) | $-57K | $0.00 |
| Net Income (TTM) | $-17M | $-44M |
| Gross Margin | -1461.1% | — |
| Operating Margin | -2396.9% | — |
| Total Debt | $1M | $937K |
| Cash & Equiv. | $16M | $5M |
DARE vs CRVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DARE
CRVS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Daré Bioscience, In… (DARE) | 100 | 23.1 | -76.9% |
| Corvus Pharmaceutic… (CRVS) | 100 | 422.9 | +322.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DARE vs CRVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CRVS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Daré Bioscience, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
DARE
Daré Bioscience, Inc.
The Income Pick
DARE is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.48
- Rev growth -99.7%, EPS growth 88.4%
- Lower volatility, beta 0.48, current ratio 0.85x
Best for: income & stability and growth exposure
CRVS
Corvus Pharmaceuticals, Inc.
The Long-Run Compounder
CRVS carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 17.1% 10Y total return vs DARE's -99.0%
- -6.6% revenue growth vs DARE's -99.7%
- 3.5% margin vs DARE's -414.3%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CRVS | -6.6% revenue growth vs DARE's -99.7% |
| Quality / Margins | CRVS | 3.5% margin vs DARE's -414.3% |
| Stability / Safety | DARE | Beta 0.48 vs CRVS's 1.63 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CRVS | +355.9% vs DARE's +0.7% |
| Efficiency (ROA) | CRVS | -35.7% ROA vs DARE's -56.8% |
DARE vs CRVS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
DARE vs CRVS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCRVSLAGGINGDARE
DAREDaré Bioscience, Inc.
1leads
CRVSCorvus Pharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs DAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DARE1/1
Valuation MetricsMultiples, price ratios, and targets
CRVS1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CRVS5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
CRVS6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DARE leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CRVS and DARE operate at a comparable scale, with $0 and -$57,130 in trailing revenue.
| Metric | DAREDaré Bioscience, … | CRVSCorvus Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | -$57,130 | $0 |
| EBITDAEarnings before interest/tax | -$16M | -$48M |
| Net IncomeAfter-tax profit | -$17M | -$44M |
| Free Cash FlowCash after capex | -$7M | -$35M |
| Gross MarginGross profit ÷ Revenue | -1461.1% | — |
| Operating MarginEBIT ÷ Revenue | -2396.9% | — |
| Net MarginNet income ÷ Revenue | -414.3% | — |
| FCF MarginFCF ÷ Revenue | +492.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -94.6% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +49.2% | -15.4% |
DARE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
CRVS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | DAREDaré Bioscience, … | CRVSCorvus Pharmaceut… |
|---|---|---|
| Market CapShares × price | $25M | $1.2B |
| Enterprise ValueMkt cap + debt − cash | $11M | $1.2B |
| Trailing P/EPrice ÷ TTM EPS | -6.06x | -27.53x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 2587.71x | — |
| Price / BookPrice ÷ Book value/share | — | 19.01x |
| Price / FCFMarket cap ÷ FCF | 5.25x | — |
CRVS leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
CRVS leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
CRVS delivers a -38.9% return on equity — every $100 of shareholder capital generates $-39 in annual profit, vs $-6 for DARE. On the Piotroski fundamental quality scale (0–9), DARE scores 4/9 vs CRVS's 3/9, reflecting mixed financial health.
| Metric | DAREDaré Bioscience, … | CRVSCorvus Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -6.1% | -38.9% |
| ROA (TTM)Return on assets | -56.8% | -35.7% |
| ROICReturn on invested capital | — | -78.1% |
| ROCEReturn on capital employed | -36.2% | -90.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | -$14M | -$4M |
| Cash & Equiv.Liquid assets | $16M | $5M |
| Total DebtShort + long-term debt | $1M | $937,000 |
| Interest CoverageEBIT ÷ Interest expense | -35.60x | -18.29x |
CRVS leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
CRVS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CRVS five years ago would be worth $50,137 today (with dividends reinvested), compared to $1,757 for DARE. Over the past 12 months, CRVS leads with a +355.9% total return vs DARE's +0.7%. The 3-year compound annual growth rate (CAGR) favors CRVS at 123.9% vs DARE's -37.6% — a key indicator of consistent wealth creation.
| Metric | DAREDaré Bioscience, … | CRVSCorvus Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +49.2% | +99.3% |
| 1-Year ReturnPast 12 months | +0.7% | +355.9% |
| 3-Year ReturnCumulative with dividends | -75.8% | +1022.3% |
| 5-Year ReturnCumulative with dividends | -82.4% | +401.4% |
| 10-Year ReturnCumulative with dividends | -99.0% | +17.1% |
| CAGR (3Y)Annualised 3-year return | -37.6% | +123.9% |
CRVS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — DARE and CRVS each lead in 1 of 2 comparable metrics.
Risk & Volatility
DARE is the less volatile stock with a 0.48 beta — it tends to amplify market swings less than CRVS's 1.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRVS currently trades 54.1% from its 52-week high vs DARE's 31.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DAREDaré Bioscience, … | CRVSCorvus Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.48x | 1.63x |
| 52-Week HighHighest price in past year | $9.19 | $26.95 |
| 52-Week LowLowest price in past year | $1.27 | $3.17 |
| % of 52W HighCurrent price vs 52-week peak | +31.7% | +54.1% |
| RSI (14)Momentum oscillator 0–100 | 70.2 | 49.2 |
| Avg Volume (50D)Average daily shares traded | 581K | 1.2M |
Evenly matched — DARE and CRVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | DAREDaré Bioscience, … | CRVSCorvus Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $33.17 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CRVS leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). DARE leads in 1 (Income & Cash Flow). 1 tied.
Best OverallCorvus Pharmaceuticals, Inc. (CRVS)Leads 3 of 6 categories
Loading custom metrics...
DARE vs CRVS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DARE or CRVS a better buy right now?
Analysts rate Corvus Pharmaceuticals, Inc.
(CRVS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DARE or CRVS?
Over the past 5 years, Corvus Pharmaceuticals, Inc.
(CRVS) delivered a total return of +401. 4%, compared to -82. 4% for Daré Bioscience, Inc. (DARE). Over 10 years, the gap is even starker: CRVS returned +17. 1% versus DARE's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DARE or CRVS?
By beta (market sensitivity over 5 years), Daré Bioscience, Inc.
(DARE) is the lower-risk stock at 0. 48β versus Corvus Pharmaceuticals, Inc. 's 1. 63β — meaning CRVS is approximately 241% more volatile than DARE relative to the S&P 500.
04Which is growing faster — DARE or CRVS?
On earnings-per-share growth, the picture is similar: Daré Bioscience, Inc.
grew EPS 88. 4% year-over-year, compared to 48. 0% for Corvus Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DARE or CRVS?
Corvus Pharmaceuticals, Inc.
(CRVS) is the more profitable company, earning 0. 0% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRVS leads at 0. 0% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — CRVS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DARE or CRVS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DARE or CRVS better for a retirement portfolio?
For long-horizon retirement investors, Daré Bioscience, Inc.
(DARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48)). Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DARE: -99. 0%, CRVS: +17. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DARE and CRVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.